10,838 Shares in CVS Health Corporation $CVS Purchased by Victory Financial Group LLC

Victory Financial Group LLC bought a new position in CVS Health Corporation (NYSE:CVS) in the 3rd quarter, HoldingsChannel reports. The fund bought 10,838 shares of the pharmacy operator’s stock, valued at approximately $929,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in CVS Health during the 2nd quarter valued at $12,747,462,000. State Street Corp raised its holdings in CVS Health by 26.3% during the second quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock worth $7,751,205,000 after purchasing an additional 15,604,883 shares in the last quarter. Wellington Management Group LLP raised its holdings in CVS Health by 49.8% during the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock worth $3,496,725,000 after purchasing an additional 11,233,381 shares in the last quarter. Bank of America Corp DE boosted its stake in CVS Health by 148.0% during the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after purchasing an additional 13,836,701 shares in the last quarter. Finally, Pzena Investment Management LLC bought a new position in CVS Health during the 2nd quarter valued at $1,217,558,000. 80.66% of the stock is owned by institutional investors.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: A bullish preview upgraded CVS to “buy” with a $115 price target, citing accelerating earnings, higher guidance, improved margins, lower leverage, strong free cash flow and a sustainable dividend. CVS previously reported quarterly revenue growth of 7.3% and EPS well above consensus. CVS Q3 Preview: Accelerating Growth, Near 3% Yield, Meaningful Upside Long-Term
• Positive Sentiment: CVS is reportedly piloting a program that expands pharmacists’ role in chronic-care management. If successful, the initiative could improve patient engagement, support care outcomes and create additional healthcare-service revenue opportunities. CVS Health is reportedly piloting pharmacists in chronic health management
• Neutral Sentiment: Analysts’ average recommendation remains equivalent to “buy,” but the reports caution that consensus ratings can be overly optimistic and should not be viewed as a standalone investment signal. Brokers Suggest Investing in CVS Health
• Negative Sentiment: CVS and its Aetna unit sued to challenge Medicare Advantage star ratings that could reduce payments by approximately $2 billion. The litigation highlights potentially material pressure on the company’s government-benefits business and creates uncertainty around future earnings. CVS sues to prevent $2B Medicare Advantage star ratings hit
• Negative Sentiment: The University of Kentucky sued CVS, alleging RICO violations and claiming the university is owed $41 million. The case adds another legal overhang and could raise costs or reputational concerns if the allegations gain traction. UK sues CVS, accuses the pharmacy of RICO
• Negative Sentiment: Pharmacy workers in Rhode Island rallied over staffing and contract issues, signaling continued labor and operating challenges across CVS’s retail footprint. CVS workers in Rhode Island rally over staffing

CVS Health Stock Performance

Shares of CVS stock opened at $89.99 on Thursday. The company has a market capitalization of $115.10 billion, a price-to-earnings ratio of 23.81, a P/E/G ratio of 0.87 and a beta of 0.60. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The stock’s fifty day simple moving average is $91.36 and its 200-day simple moving average is $88.67.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be issued a $0.6650 dividend. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.0%. CVS Health’s dividend payout ratio is currently 70.37%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CVS shares. Truist Financial raised their price objective on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Robert W. Baird set a $107.00 price target on CVS Health in a report on Thursday, August 6th. BMO Capital Markets set a $112.00 price objective on CVS Health in a report on Wednesday, September 9th. JPMorgan Chase & Co. upped their price target on shares of CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, HSBC reaffirmed a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a research note on Monday, July 6th. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

CVS Health Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.